Zacks Investment Research upgraded shares of CSPC Pharmaceutical Group (OTCMKTS:CHPTY) from a sell rating to a hold rating in a research report sent to investors on Thursday, November 16th.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
CSPC Pharmaceutical Group (OTCMKTS:CHPTY) remained flat at $$101.08 on Thursday. The company has a market cap of $12,620.00, a PE ratio of 39.79, a price-to-earnings-growth ratio of 1.21 and a beta of 1.31. CSPC Pharmaceutical Group has a one year low of $51.99 and a one year high of $104.77. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 0.02.
ILLEGAL ACTIVITY NOTICE: “CSPC Pharmaceutical Group (OTCMKTS:CHPTY) Upgraded to “Hold” at Zacks Investment Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/04/cspc-pharmaceutical-group-ltd-chpty-upgraded-at-zacks-investment-research.html.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
Get a free copy of the Zacks research report on CSPC Pharmaceutical Group (CHPTY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.